SPONSOR
French Innovative Leukemia Organisation
Total Trials
2
Recruiting
2
Phases
Phase 2
French Innovative Leukemia Organisation is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Richter Syndrome, AML, Adult.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — French Innovative Leukemia Organisation
How many clinical trials has French Innovative Leukemia Organisation sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by French Innovative Leukemia Organisation, of which 2 are actively recruiting participants. These trials cover conditions including Richter Syndrome, AML, Adult. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does French Innovative Leukemia Organisation research focus on?
French Innovative Leukemia Organisation clinical trials span Richter Syndrome, AML, Adult. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a French Innovative Leukemia Organisation clinical trial?
To participate in a French Innovative Leukemia Organisation trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all French Innovative Leukemia Organisation trials with current recruitment status updated daily.
Clinical Trials by French Innovative Leukemia Organisation
NCT06186648 Phase 2
Recruiting
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
Richter Syndrome
NCT06377579
Recruiting
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
AML, Adult
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology